PainReform (PRFX) has released an update.
PainReform Ltd., a clinical-stage pharmaceutical company, has been notified by Nasdaq of non-compliance with its minimum bid price rule but will remain listed during a 180-day grace period to regain compliance. The company’s stock will continue trading under the ticker ‘PRFX’ as it works towards meeting the Nasdaq’s requirements. PainReform specializes in reformulating established therapeutics and is developing PRF-110 for extended post-operative pain relief.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
